Platelet GPIb complex as a target for anti-thrombotic drug development

Kenneth J. Clemetson; Jeannine M. Clemetson

doi:10.1160/TH07-12-0718

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2008; 99(03): 473-479
DOI: 10.1160/TH07-12-0718

Theme Issue Article

Schattauer GmbH

Platelet GPIb complex as a target for anti-thrombotic drug development

Authors

Kenneth J. Clemetson

¹Theodor Kocher Institute, University of Berne, Berne, Switzerland
Jeannine M. Clemetson

¹Theodor Kocher Institute, University of Berne, Berne, Switzerland

Abstract

Summary

Specific inhibition of platelet function is a major target of antithrombotic drug research. Platelet receptors are both accessible and specific but have multiple functions often linked to a wide range of ligands. GPIb complex is best known as a major platelet receptor for vonWillebrand factor essential for platelet adhesion under high shear conditions found in arteries and in thrombosis. Recent animal studies have supported inhibition of GPIb as a good candidate for anti-thrombotic drug development with several classes of proteins showing important specific effects and the required discrimination between roles in haemo- stasis and thrombosis is important to protect against bleeding complications.These include antibodies, several classes of snake venom proteins, mutant thrombin molecules and peptides affecting subunit interactions.However,due to the nature of its receptor- ligand interactions involving large protein-protein interfaces, the possibility of developing classic pharmaceutical inhibitors for long term (and perhaps oral) treatment is still unclear, and additional information about structural interactions and signalling mechanisms is essential.

Keywords

Antiplatelet agents - atherothrombosis - GP Ib - platelet glycoproteins - platelet pharmacology

Volltext

Referenzen

References
1 Kempton CL, Harvey RD, 3rd Roberts HR. Novel therapeutic agents in the management of hemorrhage and thrombosis. Cardiovasc Hematol Agents Med Chem 2006; 4: 319-334.
2 Thiagarajan P. New targets for antithrombotic drugs. Am J Cardiovasc Drugs 2002; 2: 227-235.
3 Miner J, Hoffhines A. The discovery of aspirin’s antithrombotic effects. Tex Heart Inst J 2007; 34: 179-186.
4 Tricoci P, Peterson ED. The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients. J Interv Cardiol 2006; 19: 449-455.
5 Storey RF, Husted S, Harrington RA. et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50: 1852-1856.
6 Leger AJ, Jacques SL, Badar J. et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet- mediated thrombosis. Circulation 2006; 113: 1244-1254.
7 Choi S, Vilaire G, Marcinkiewicz C. et al. Small molecule inhibitors of integrin α2β1. J Med Chem 2007; 50: 5457-5462.
8 Clemetson KJ, Clemetson JM. Collagen receptors as potential targets for novel anti-platelet agents. Curr Pharm Des 2007; 13: 2673-2683.
9 Funk CD, Fitzgerald GA. COX-2 Inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007; 50: 470-479.
10 Diaz-Ricart M, Palomo M, Fuste B. et al. Inhibition of tyrosine kinase activity prevents the adhesive and cohesive properties of platelets and the expression of procoagulant activity in response to collagen. Thromb Res 2007; 26: 26.
11 Kurisaki T, Taylor RG, Hartshorne DJ. Effects of the protein phosphatase inhibitors, tautomycin and calyculin-A, on protein phosphorylation and cytoskeleton of human platelets. Cell Struct Funct 1995; 20: 331-343.
12 Hirsch E, Bosco O, Tropel P. et al. Resistance to thromboembolism in PI3Kγ-deficient mice. FASEB J 2001; 15: 2019-2021.
13 Hawkins PT, Stephens LR. PI3Kγ is a key regulator of inflammatory responses and cardiovascular homeostasis. Science 2007; 318: 64-66.
14 Coller BS, Peerschke EI, Scudder LE. et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic- like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-338.
15 Coller BS, Peerschke EI, Scudder LE. et al. Studies with a murine monoclonal antibody that abolishes ristocetin- induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood 1983; 61: 99-110.
16 Scarborough RM, Naughton MA, Teng W. et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb- IIIa. J Biol Chem 1993; 268: 1066-1073.
17 Hanson J, De Leval X, David JL. et al. Progress in the field of GPIIb/IIIa antagonists. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 157-167.
18 Wiviott SD, Antman EM, Winters KJ. et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111: 3366-3373.
19 Kim YB, Jin J, Dangelmaier C. et al. The P2Y1 receptor is essential for ADP-induced shape change and aggregation in mouse platelets. Platelets 1999; 10: 399-406.
20 Fung CY, Cendana C, Farndale RW. et al. Primary and secondary agonists can use P2X(1) receptors as a major pathway to increase intracellular Ca(2+) in the human platelet. J Thromb Haemost 2007; 5: 910-917.
21 Derian CK, Damiano BP, Addo MF. et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 2003; 304: 855-861.
22 Wu CC, Hwang TL, Liao CH. et al. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3. Thromb Haemost 2002; 87: 1026-1033.
23 Clemetson KJ, Clemetson JM. Platelet collagen receptors. Thromb Haemost 2001; 86: 189-197.
24 Vanhoorelbeke K, Ulrichts H, Van De Walle G. et al. Inhibition of platelet glycoprotein Ib and its antithrombotic potential. Curr Pharm Des 2007; 13: 2684-2697.
25 Gruner S, Prostredna M, Koch M. et al. Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice. Blood 2005; 105: 1492-1499.
26 Li H, Lockyer S, Concepcion A. et al. The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats. Arterioscler Thromb Vasc Biol 2007; 27: 1199-1205.
27 Lopez JA, Dong JF. Shear stress and the role of high molecular weight von Willebrand factor multimers in thrombus formation. Blood Coagul Fibrinolysis 2005; 16: S11-16.
28 Dubois C, Panicot-Dubois L, Gainor JF. et al. Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. J Clin Invest 2007; 117: 953-960.
29 Nonne C, Lenain N, Hechler B. et al. Importance of platelet phospholipase Cγ2 signaling in arterial thrombosis as a function of lesion severity. Arterioscler Thromb Vasc Biol 2005; 25: 1293-1298.
30 Dubois C, Panicot-Dubois L, Merrill-Skoloff G. et al. Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood 2006; 107: 3902-3906.
31 Siljander PR, Munnix IC, Smethurst PA. et al. Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. Blood 2004; 103: 1333-1341.
32 Sarratt KL, Chen H, Zutter MM. et al. GPVI and α2β1 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow. Blood 2005; 106: 1268-1277.
33 Bergmeier W, Piffath CL, Goerge T. et al. The role of platelet adhesion receptor GPIbα far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci USA 2006; 103: 16900-16905.
34 Cauwenberghs N, Meiring M, Vauterin S. et al. Antithrombotic effect of platelet glycoprotein Ibblocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol 2000; 20: 1347-1353.
35 Bernard J, Soulier JP. Sur une nouvelle variété de dystrophie thrombocytaire-hémorragipare congénitale. Semin Hôp Paris 1948; 24: 3217-3223.
36 Nurden AT. Qualitative disorders of platelets and megakaryocytes. JThromb Haemost 2005; 3: 1773-1782.
37 Clemetson KJ, McGregor JL, James E. et al. Characterization of the platelet membrane glycoprotein abnormalities in Bernard-Soulier syndrome and comparison with normal by surface-labeling techniques and high-resolution two-dimensional gel electrophoresis. J Clin Invest 1982; 70: 304-311.
38 Wright SD, Michaelides K, Johnson DJD. et al. Double heterozygosity for mutations in the platelet glycoprotein IX gene in three siblings with Bernard-Soulier syndrome. Blood 1993; 81: 2339-2347.
39 Clemetson JM, Kyrle PA, Brenner B. et al. Variant Bernard-Soulier syndrome associated with a homozygous mutation in the leucine-rich domain of glycoprotein IX. Blood 1994; 84: 1124-1131.
40 Ware J, Russell S, Ruggeri ZM. Cloning of the murine platelet glycoprotein Ibalpha gene highlighting species-specific platelet adhesion. Blood Cells Mol Dis 1997; 23: 292-301.
41 Strassel C, Nonne C, Eckly A. et al. Decreased thrombotic tendency in mouse models of the Bernard- Soulier syndrome. Arterioscler Thromb Vasc Biol 2007; 27: 241-247.
42 Kanaji T, Russell S, Ware J. Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome. Blood 2002; 100: 2102-2107.
43 Clemetson KJ. A short history of platelet glycoprotein Ib complex. Thromb Haemost 2007; 98: 63-68.
44 Dormann D, Clemetson KJ, Kehrel BE. The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood 2000; 96: 2469-2478.
45 Adam F, Guillin MC, Jandrot-Perrus M. Glycoprotein Ib-mediated platelet activation. A signalling pathway triggered by thrombin. Eur J Biochem 2003; 270: 2959-2970.
46 Weeterings C, Adelmeijer J, Myles T. et al. Glycoprotein Ibalpha-mediated platelet adhesion and aggregation to immobilized thrombin under conditions of flow. Arterioscler Thromb Vasc Biol 2006; 26: 670-675.
47 Romo GM, Dong JF, Schade AJ. et al. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med 1999; 190: 803-814.
48 Jurk K, Clemetson KJ, De Groot PG. et al. Thrombospondin- 1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB J 2003; 17: 1490-1492.
49 Gralnick HR, Williams S, McKeown L. et al. A monomeric von Willebrand factor fragment, Leu- 504-Ser-728, inhibits von Willebrand factor interaction with glycoprotein Ib-IX. Proc Natl Acad Sci USA 1992; 89: 7880-7884.
50 Sixma JJ, Ijsseldijk MJ, Hindriks G. et al. Adhesion of blood platelets is inhibited by VCL, a recombinant fragment (leucine504 to lysine728) of von Willebrand factor. Arterioscler Thromb Vasc Biol 1996; 16: 64-71.
51 Kinlough-Rathbone RL, Perry DW, Rand ML. et al. Responses to aggregating agents after cleavage of GPIb of human platelets by the O-sialoglycoprotein endoprotease from Pasteurella haemolytica- potential surrogates for Bernard-Soulier platelets?. Thromb Res 2000; 99: 165-172.
52 Ward CM, Andrews RK, Smith AI. et al. Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibα. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibα as a binding site for von Willebrand factor and α-thrombin. Biochemistry 1996; 35: 4929-4938.
53 Hamako J, Matsui T, Nishida S. et al. Purification and characterization of kaouthiagin, a von Willebrand factor-binding and -cleaving metalloproteinase fromNaja kaouthia cobra venom. Thromb Haemost 1998; 80: 499-505.
54 De Luca M, Facey DA, Favaloro EJ. et al. Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin- dependent activation. Blood 2000; 95: 164-172.
55 Shen Y, Dong JF, Romo GM. et al. Functional analysis of the C-terminal flanking sequence of platelet glycoprotein Ibalpha using canine-human chimeras. Blood 2002; 99: 145-150.
56 Cauwenberghs N, Vanhoorelbeke K, Vauterin S. et al. Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibα. Blood 2001; 98: 652-660.
57 Uff S, Clemetson JM, Harrison T. et al. Crystal Structure of the platelet Glycoprotein Ibα N-terminal domain reveals an unmasking mechanism for receptor activation. J Biol Chem 2002; 277: 35657-35663.
58 Huizinga EG, Tsuji S, Romijn RA. et al. Structures of glycoprotein Iba and its complex with von Willebrand factor A1 domain. Science 2002; 297: 1176-1179.
59 Dumas JJ, Kumar R, McDonagh T. et al. Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibα complex reveals conformation differences with a complex bearing von Willebrand disease mutations. J Biol Chem 2004; 279: 23327-23334.
60 Dumas JJ, Kumar R, Seehra J. et al. Crystal structure of the GpIbα-thrombin complex essential for platelet aggregation. Science 2003; 301: 222-226.
61 Celikel R, McClintock RA, Roberts JR. et al. Modulation of a-thrombin function by distinct interactions with platelet glycoprotein Ibα. Science 2003; 301: 218-221.
62 Wu G, Essex DW, Meloni FJ. et al. Human endothelial cells in culture and in vivo express on their surface all four components of the glycoprotein Ib/IX/V complex. Blood 1997; 90: 2660-2669.
63 Kleinschnitz C, Pozgajova M, Pham M. et al. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007; 115: 2323-2330.
64 Jain S, Zuka M, Liu J. et al. Platelet glycoprotein Ibα supports experimental lung metastasis. Proc Natl Acad Sci USA 2007; 104: 9024-9028.
65 Lu Q, Navdaev A, Clemetson JM. et al. Snake venom C-type lectins interacting with platelet receptors. Structure-function relationships and effects on haemostasis. Toxicon 2005; 45: 1089-1098.
66 Clemetson KJ, Lu Q, Clemetson JM. Snake venom proteins affecting platelets and their applications to anti-thrombotic research. Curr Pharm Des 2007; 13: 2887-2892.
67 Peng M, Lu W, Beviglia L. et al. Echicetin: A snake venom protein that inhibits binding of von Willebrand factor and alboaggregins to platelet glycoprotein Ib. Blood 1993; 81: 2321-2328.
68 Navdaev A, Dormann D, Clemetson JM. et al. Echicetin, a GPIb-binding snake C-type lectin from Echis carinatus, also contains a binding site for IgMk responsible for platelet agglutination in plasma and inducing signal transduction. Blood 2001; 97: 2333-2341.
69 Peng M, Emig FA, Mao A. et al. Interaction of echicetin with a high affinity thrombin binding site on platelet glycoprotein GPIb. Thromb Haemost 1995; 74: 954-957.
70 Fukuda K, Doggett T, Laurenzi IJ. et al. The snake venom protein botrocetin acts as a biological brace to promote dysfunctional platelet aggregation. Nat Struct Mol Biol 2005; 12: 152-159.
71 Maita N, Nishio K, Nishimoto E. et al. Crystal structure of von Willebrand factor A1 domain complexed with snake venom, bitiscetin: insight into glycoprotein Ibα binding mechanism induced by snake venom proteins. J Biol Chem 2003; 278: 37777-37781.
72 Fukuda K, Mizuno H, Atoda H. et al. Crystal structure of flavocetin-A, a platelet glycoprotein Ib-binding protein, reveals a novel cyclic tetramer of C-type lectinlike heterodimers. Biochemistry 2000; 39: 1915-1923.
73 Huang KF, Ko TP, Hung CC. et al. Crystal structure of a platelet-agglutinating factor isolated from the venom of Taiwan habu (Trimeresurus mucrosquamatus). Biochem J 2004; 378: 399-407.
74 Lu Q, Clemetson JM, Clemetson KJ. Translocation of GPIb and Fc receptor γ-chain to cytoskeleton in mucetin-activated platelets. J Thromb Haemost 2005; 3: 2065-2076.
75 Polgar J, Clemetson JM, Kehrel BE. et al. Platelet activation and signal transduction by convulxin, a C-type lectin from Crotalus durissus terrificus (tropical rattlesnake) venom via the p62/GPVI collagen receptor. J Biol Chem 1997; 272: 13576-13583.
76 Lee WH, Du XY, Lu QM. et al. Stejnulxin, a novel snake C-type lectin-like protein fromTrimeresurus stejnegeri venom is a potent platelet agonist acting specifically via GPVI. Thromb Haemost 2003; 90: 662-671.
77 Du XY, Clemetson JM, Navdaev A. et al. Ophioluxin, a convulxin-like C-type lectin from Ophiophagus hannah (King cobra) is a powerful platelet activator via glycoprotein VI. J Biol Chem 2002; 277: 35124-35132.
78 Kato K, Furihata K, Cheli Y. et al. Effect of multimer size and a natural dimorphism on the binding of convulxin to platelet glycoprotein (GP)VI. J Thromb Haemost 2006; 4: 1107-1113.
79 Krem MM, Di Cera E. Dissecting substrate recognition by thrombin using the inactive mutant S195A. Biophys Chem 2003; 100: 315-323.
80 Berny MA, White TC, Tucker EI. et al. Thrombin mutant W215A/E217A acts as a platelet GPIb antagonist. Arterioscler Thromb Vasc Biol 2007; 25: 25.
81 Ruggeri ZM. Von Willebrand factor: looking back and looking forward. Thromb Haemost 2007; 98: 55-62.
82 White T, Berny M, Fernandez J. et al. Glycoprotein Ib mediates platelet recruitment, activation and aggregation on immobilized Protein C and activated Protein C under shear. J. Thromb Haemost 2007; 5 (Suppl. 02) O-M-030.
83 Phillips MD, Moake JL, Nolasco L. et al. Aurin tricarboxylic acid: a novel inhibitor of the association of von Willebrand factor and platelets. Blood 1988; 72: 1898-1903.
84 Weinstein M, Vosburgh E, Phillips M. et al. Isolation from commercial aurintricarboxylic acid of the most effective polymeric inhibitors of von Willebrand factor interaction with platelet glycoprotein Ib. Comparison with other polyanionic and polyaromatic polymers. Blood 1991; 78: 2291-2298.
85 Yin H, Slusky JS, Berger BW. et al. Computational design of peptides that target transmembrane helices. Science 2007; 315: 1817-1822.
86 David T, Ohlmann P, Eckly A. et al. Inhibition of adhesive and signaling functions of the platelet GPIb- V-IX complex by a cell penetrating GPIbα peptide. J Thromb Haemost 2006; 4: 2645-2655.
87 Feng S, Resendiz JC, Lu X. et al. Filamin A binding to the cytoplasmic tail of glycoprotein Ibα regulates von Willebrand factor-induced platelet activation. Blood 2003; 102: 2122-2129.
88 Feng S, Christodoulides N, Resendiz JC. et al. Cytoplasmic domains of GpIbα and GpIbβ regulate 14-3–3ζ binding to GpIb/IX/V. Blood 2000; 95: 551-557.
89 Smith T, Benard S, Jacob J. et al. Identification of potent cyclic peptides that bind to platelet glycoprotein Iba and selectively inhibit von Willebrand factor dependent high-shear platelet aggregation. J Thromb Haemostas 2007; 5 (Suppl. 02) P-W-265.